Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study
Year: 2020
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Rheumatology
Authors: Benjamin A Fisher, Antonia Szanto, Wan-Fai Ng, Michele Bombardieri, Maximilian G Posch, Athena S Papas, Arwa M Farag, Thomas Daikeler, Bettina Bannert, Diego Kyburz, Alan J Kivitz, Steven E Carsons, David A Isenberg, Francesca Barone, Simon J Bowman, Pascal Espié, David Floch, Cyrielle Dupuy, Xiaohui Ren, Petra M Faerber, Andrew M Wright, Hans-Ulrich Hockey, Michael Rotte, Julie Milojevic, Alexandre Avrameas, Marie-Anne Valentin, James S Rush, Peter Gergely
Institutions: University Hospitals Birmingham NHS Foundation Trust, National Institute for Health and Care Research, NIHR Birmingham Biomedical Research Centre, University of Birmingham, University of Debrecen, Newcastle upon Tyne Hospitals NHS Foundation Trust, NIHR Newcastle Biomedical Research Centre, Newcastle University, Queen Mary University of London, William Harvey Research Institute, Charité – Universitätsmedizin Berlin, Tufts University, King Abdulaziz University, University Hospital of Basel, Altoona Center for Clinical Research, New York University, University College Hospital, University College London Hospitals NHS Foundation Trust, Novartis Institutes for BioMedical Research, Novartis (Switzerland)
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3001806477